Trial Profile
A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Aug 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Romidepsin (Primary)
- Indications Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 05 Aug 2023 Planned End Date changed from 31 Jul 2023 to 31 Jul 2024.
- 05 Aug 2023 Planned primary completion date changed from 31 Jul 2023 to 31 Jul 2024.
- 30 Jan 2023 Planned End Date changed from 30 Nov 2021 to 31 Jul 2023.